Inhibitory effect of luteolin on the metabolism of vandetanib in vivo and in vitro

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 3, 2025

This study aimed to examine the potential drug-drug interaction (DDI) between vandetanib and luteolin in vivo vitro , with objective of establishing a scientific foundation for their appropriate utilization clinical settings. Sprague-Dawley (SD) rats were randomly divided into two groups: control group (vandetanib administered by gavage alone) an experimental together). A series blood samples collected at different time intervals. The plasma concentrations its metabolite N-demethyl determined using ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Incubation systems set up rat liver microsomes (RLM) human (HLM) measure Michaelis-Menten constant (K m ) half-maximum inhibitory concentration (IC 50 values. Additionally, mechanism on was also investigated. Ultimately, molecular inhibition examined through docking techniques. In animal experiment results showed that compared group, AUC (0-t) C max significantly increased. findings from experiments revealed exhibited moderate effect metabolism vandetanib. IC values RLM HLM be 8.56 μM 15.84 μM, respectively. identified classified as mixed. utilized analysis provide additional evidence supporting competitive CYP3A4. data presented our indicated luteolin, which may necessitate need dose adjustment during co-administration

Язык: Английский

---

Natural products modulating MAPK for CRC treatment: a promising strategy

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 5, 2025

Colorectal cancer (CRC) is a common malignant tumor of the digestive system, and pathogenic mechanism still unclear, mostly related to genetics, immunity, inflammation, abnormal activation tumor-related signaling pathways. MAPK belongs Ser/Thr kinase family, which plays an important role in complex cellular programs such as regulation cell proliferation, differentiation, apoptosis, angiogenesis, metastasis. Increasing evidence supports that highly correlated with risk CRC. Targeting may be therapeutic strategy, natural products show great potential regulating MAPK-related proteins. In this paper, we searched PubMed, Web Science CNKI databases keywords "colorectal cancer, products, pathway, ERK, P38, JNK" for relevant studies last 14 years from 2010 2024. This work retrieved 47 studies, aiming provide new strategies CRC patients lay foundation drug development.

Язык: Английский

---

Luteolin: a natural product with multiple mechanisms for atherosclerosis

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 27, 2025

Atherosclerosis (AS) is a degenerative and proliferative disease characterised by the deposition of lipid and/or fibrous substances within intima arteries. The pathological mechanisms AS involve endothelial cell (EC) injury dysfunction, vascular smooth muscle (VSMC) migration proliferation, foam formation, inflammatory recruitment, abnormal platelet activation aggregation. In recent years, incidence mortality rates atherosclerotic cardiovascular (ASCVD), which has as its basis, have shown an upward trend globally. Currently, available therapeutic agents (such statins, PCSK9 inhibitors, antiplatelet drugs) can, to some extent, delay progression AS; however, many these drugs adverse effects or are not suitable for long-term use, potentially causing severe negative impacts on patients’ lives work. Therefore, development safe effective holds immense social economic significance. natural compounds derived from plants gradually emerged source new treating AS. Luteolin (3′,4′,5,7-tetrahydroxyflavone) common plant-derived flavonoid widely found in various vegetables fruits, including celery, parsley, broccoli, onion leaves, carrots, peppers, cabbage, apples, chrysanthemums. Numerous preclinical studies revealed that luteolin exhibits significant anti-AS effects. This article comprehensively reviews Lu cells (endothelial cells, macrophages, neutrophils) under experimental conditions regulatory risk factors (hypertension, hyperglycemia, dyslipidemia), providing strong evidential basis clinical application mechanistic research luteolin.

Язык: Английский

---

Dihydroartemisinin inhibits lung cancer bone metastasis by modulating macrophage polarization

European journal of medical research, Год журнала: 2025, Номер 30(1)

Опубликована: Апрель 5, 2025

The high metastasis rate of lung cancer contributes to its low 5-year survival rate. Bone is a common complication in advanced cancer, adversely affecting postoperative recovery. This study investigates the effects DHA on macrophage polarization and underlying mechanisms. In vitro, was found inhibit M2 while promoting M1 macrophages, thereby reducing invasion migration cells. vivo, inhibited growth bone by modulating M1/M2 both tissues metastatic sites. addition, through CCL2/CCR2 pathway, decreased recruitment accumulation. These results suggest that effective inhibiting metastasis, offering promising research application prospects.

Язык: Английский

---

3D Bioprinted Biomimetic MOF-Functionalized Hydrogel Scaffolds for Bone Regeneration: Synergistic Osteogenesis and Osteoimmunomodulation

Materials Today Bio, Год журнала: 2025, Номер unknown, С. 101740 - 101740

Опубликована: Апрель 1, 2025

Язык: Английский

---